Contact our support team if you have any enquiries about any of our products
Call: (856) 848-8698
PIFA® technology is a cutting-edge, patented immunoassay method which rapidly, easily, and accurately detects target antigens or antibodies.
PIFA® technology is based on the selective filtration of microparticles in response to antibody/antigen binding. Dyed microparticles coated with antigens or antibodies determine the visual signal for the results of the assay. The presence of a corresponding antibody or antigen in the test sample results in the formation of a matrix of microparticles, which are more susceptible to filtration. The inability of these matrixed microparticles to move through the filter, and the resulting color change in the reagent mixture, signal positive reactivity of the test sample (e.g. the presence of target antigens or antibodies).
Key features of PIFA® technology make it advantageous for a broad array of uses:
PIFA® technology is currently used in commercially available and/or developmental tests for:
PIFA® technology is available for licensing. To inquire about licensing or for technical inquiries, please contact us.
Akers Biosciences, Inc. holds patents related to PIFA® Technology.
U.S. patent nos. 5,565,366, 5,827,749, and 7,896,167; other patents pending.
News Alert Service
Sign up to receive email alerts of our latest news
Akers Biosciences, Inc. © 2017